{"id":"clobetasol-propionate-alone","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin atrophy"},{"rate":null,"effect":"Striae"},{"rate":null,"effect":"Telangiectasia"},{"rate":null,"effect":"Systemic corticosteroid absorption (with prolonged use or occlusion)"},{"rate":null,"effect":"Local irritation or burning"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clobetasol propionate is a Class I (super-potent) corticosteroid that works by activating intracellular glucocorticoid receptors, leading to decreased production of inflammatory cytokines, reduced immune cell infiltration, and suppression of local inflammatory cascades. This results in rapid reduction of erythema, pruritus, and other inflammatory skin manifestations. The drug is applied topically and acts locally at the site of inflammation.","oneSentence":"Clobetasol propionate is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:42:07.234Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., psoriasis, lichen planus, severe eczema)"},{"name":"Alopecia areata"}]},"trialDetails":[{"nctId":"NCT06135402","phase":"NA","title":"Comparison of Laser Treatment With Clobetasol Therapy in Patients With Lichen Sclerosus","status":"RECRUITING","sponsor":"Kantonsspital Winterthur KSW","startDate":"2023-11-10","conditions":"Lichen Sclerosus","enrollment":120},{"nctId":"NCT06856590","phase":"NA","title":"ZINCLO-HAND: Zinc and Clobetasol for the Prevention of Regorafenib-Induced Hand-Foot Skin Reaction","status":"COMPLETED","sponsor":"Gazi University","startDate":"2025-02-20","conditions":"Hand-Foot Skin Reaction (HFSR)","enrollment":150},{"nctId":"NCT05243563","phase":"PHASE2, PHASE3","title":"Does Steroid Plus CO2 Laser Improve Lichen Sclerosus Symptoms Compared to Steroids Alone?","status":"TERMINATED","sponsor":"University of South Alabama","startDate":"2022-04-13","conditions":"Vulvar Lichen Sclerosus","enrollment":11},{"nctId":"NCT02355639","phase":"PHASE1","title":"A Single-Centre Clinical Trial to Assess Steroid Induced Skin Atrophy on Healthy Skin","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-01","conditions":"Skin and Connective Tissue Diseases","enrollment":16},{"nctId":"NCT01043224","phase":"PHASE1","title":"A Psoriasis Plaque Test Comparing Products for the Treatment of Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2010-01","conditions":"Psoriasis Vulgaris","enrollment":24},{"nctId":"NCT03179605","phase":"PHASE2","title":"Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06","status":"TERMINATED","sponsor":"Primus Pharmaceuticals","startDate":"2017-05-02","conditions":"Psoriasis","enrollment":22},{"nctId":"NCT04719962","phase":"NA","title":"Direct Diagnosis of Disseminated Lyme Borreliosis.","status":"UNKNOWN","sponsor":"University Hospital, Strasbourg, France","startDate":"2021-07-07","conditions":"Lyme Disease","enrollment":10},{"nctId":"NCT02313870","phase":"PHASE3","title":"Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2008-01-22","conditions":"Bullous Pemphigoid","enrollment":322},{"nctId":"NCT03779360","phase":"NA","title":"Intradermal LPS and Antibiotics","status":"COMPLETED","sponsor":"Centre for Human Drug Research, Netherlands","startDate":"2018-10-12","conditions":"Inflammation; Skin","enrollment":32},{"nctId":"NCT03983460","phase":"NA","title":"Dupilumab Impact on Skin Resident Memory T Cells","status":"UNKNOWN","sponsor":"Association pour la Recherche Clinique et Immunologique","startDate":"2020-03-09","conditions":"Atopic Dermatitis","enrollment":20},{"nctId":"NCT03758365","phase":"PHASE1","title":"Evaluation of the Vasoconstriction Properties of MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2018-11-05","conditions":"Vasoconstriction","enrollment":36},{"nctId":"NCT00864500","phase":"PHASE1","title":"Pivotal Bioequivalence Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2005-11","conditions":"Healthy","enrollment":224},{"nctId":"NCT00864240","phase":"PHASE1","title":"The Dose-response \"Pilot\" Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2005-10","conditions":"Healthy","enrollment":15},{"nctId":"NCT03584360","phase":"PHASE2","title":"Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2018-09-24","conditions":"Psoriasis Vulgaris","enrollment":30},{"nctId":"NCT02936492","phase":"PHASE1","title":"BAY1003803 Single and Multiple Dose Escalation, Safety, Tolerability and Pharmacokinetics Study","status":"TERMINATED","sponsor":"Bayer","startDate":"2016-10-24","conditions":"Psoriasis","enrollment":32},{"nctId":"NCT02492373","phase":"NA","title":"Topical Corticosteroids on the Incidence of Postinflammatory Hyperpigmentation After QsNdYAG Laser","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2015-02","conditions":"Lentigines, Post Inflammatory Hyperpigmentation","enrollment":21},{"nctId":"NCT00769184","phase":"NA","title":"Combining Topical Corticosteroid and LCD Treatment for Localized Plaque Psoriasis","status":"COMPLETED","sponsor":"NeoStrata Company, Inc.","startDate":"2008-10","conditions":"Psoriasis","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"clobetasol propionate alone","genericName":"clobetasol propionate alone","companyName":"University Hospital, Montpellier","companyId":"university-hospital-montpellier","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clobetasol propionate is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors. Used for Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., psoriasis, lichen planus, severe eczema), Alopecia areata.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}